Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Warner Bros. Discovery Weighs Renewed Sale Talks With Paramount Skydance Amid Netflix Deal Review 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
OpenAI Hires OpenClaw Creator Peter Steinberger to Advance Next-Generation AI Agents 
Freedom Finance and Binance Join Forces in Digital Assets 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
TUCSON, Ariz., April 27, 2018 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial results for the quarter ended March 31, 2018 after the market close on Thursday, May 10. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.
| Conference Call & Webcast Details | ||
| Date: | Thursday, May 10 | |
| Time: | 4:30pm Eastern Time | |
| Toll Free: | 866-548-4713 | |
| International: | 323-794-2093 | |
| Conference ID: | 5477857 | |
| Webcast: | http://public.viavid.com/index.php?id=129155 | |
About HTG:
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
CONTACT:
Ashley Robinson
LifeSci Advisors, LLC
617-775-5956
[email protected]
TJ Johnson
President/CEO
HTG Molecular Diagnostics
520-547-2827 x130
[email protected]
